BioCentury
ARTICLE | Clinical News

Celltrion to begin clinical trials of Remsima in China

June 2, 2017 7:18 PM UTC

Celltrion Inc. (KOSDAQ:068270) said it has received clearance from China FDA to begin clinical trials of Remsima biosimilar infliximab. The company said it will become the first non-Chinese company to begin clinical studies of a biosimilar mAb in China.

Celltrion declined to say when the first study will begin, but noted that the company submitted an IND to CFDA for Remsima in January 2014. The mAb against tumor necrosis factor (TNF) alpha is a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ), which is approved to treat autoimmune diseases including rheumatoid arthritis (RA), psoriasis and Crohn's disease (CD)...

BCIQ Company Profiles

Celltrion Inc.

Pfizer Inc.